Starpharma Holdings Limited (SPHRY)
OTCMKTS · Delayed Price · Currency is USD
0.8900
0.00 (0.00%)
Sep 8, 2025, 8:00 PM EDT
Starpharma Holdings Revenue
In the fiscal year ending June 30, 2025, Starpharma Holdings had annual revenue of 5.85M AUD, down -40.04%. Starpharma Holdings had revenue of 3.42M in the half year ending June 30, 2025, with 30.05% growth.
Revenue
5.85M AUD
Revenue Growth
-40.04%
P/S Ratio
9.03
Revenue / Employee
146.25K AUD
Employees
40
Market Cap
34.62M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 5.85M | -3.91M | -40.04% |
Jun 30, 2024 | 9.76M | 5.41M | 124.64% |
Jun 30, 2023 | 4.34M | -819.00K | -15.87% |
Jun 30, 2022 | 5.16M | 1.68M | 48.04% |
Jun 30, 2021 | 3.49M | -3.63M | -50.99% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Starpharma Holdings News
- 2 years ago - Starpharma: Patience Needed, But A Lot To Like - Seeking Alpha
- 3 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 3 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 4 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 4 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 4 years ago - Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma - Seeking Alpha
- 4 years ago - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack - Seeking Alpha
- 4 years ago - Starpharma Up With News, Down With None; Timing Entry Makes Sense - Seeking Alpha